ACB · Aurora Cannabis Inc.

Current Thesis

ACB is a sentiment-beta proxy on the U.S. cannabis-reschedule trade, and it remains the wrong horse. Aurora is a Canadian LP with no U.S. THC operations, so the economic catalyst the April 24 2026 DOJ/DEA order moving FDA-approved + state-licensed medical product to Schedule III and killing 280E for U.S. medical operators does not accrue to it. The live tape proves the point: into the June 29 DEA broad-rescheduling hearing, the U.S. operator complex is ripping (MSOS +7.6% to $5.10 on June 4 2026, TLRY +~4% pre-market), yet ACB sits at ~$3.46–3.59, glued to its 52-week LOW of $3.07 versus a $6.67 high. The name lags the very rally its theme is driving. Two back-to-back binaries frame the next month: Q4/FY26 earnings June 11 (pre-open) and the DEA hearing June 29.

Bull Case

• Medical-first pivot is producing actual profit: medical net revenue $76.2M in Q3 FY26 (+12% YoY), a record 81% of consolidated net revenue and 95% of adjusted gross profit (Q3 FY26 6-K). High-margin international medical (Germany, Poland, Australia, UK) carries roughly 2.5x the margin of dead Canadian rec.
• Guidance points to cash generation: FY26 global medical net revenue guided $269–281M (+10–15%); consolidated adjusted EBITDA $52–57M (+5–10% YoY) a rare positive-EBITDA cannabis name.
• Sector sentiment is re-accelerating into a hard date: MSOS broke out +7.6% to a $5.10 close on June 4 2026 with CGC, ACB, CRON tagging along, all front-running the June 29 DEA hearing. On June 5 the White House pushed Congress to preserve legal hemp CBD (Marijuana Moment) bullish policy headlines are clustering, and ACB rips on beta when the complex gaps.
• Balance sheet de-risked: after years of dilution and asset sales, a net-cash position removes the near-term solvency overhang that still haunts several peers.

Bear Case

• The catalyst does not pay this ticker. 280E relief and Schedule-III medical reclassification are U.S.-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). The June 4 divergence MSOS +7.6% while ACB held near $3.46 is the live proof that capital is rewarding U.S. exposure, not a Canadian LP.
• Price structure is broken: ~$3.46 against a $3.07–6.67 52-week range puts it in the bottom decile, below the 20-, 50- and 200-DMAs. That is mean-reversion-down structure with no momentum leg to buy.
• Recreational stays Schedule I per the April 24 order. The June 29 hearing (running through ~July 15, recess July 3, reconvene July 6) could expand scope to recreational, but a broad reschedule is far from assured and faces formal rulemaking, comment and appeal risk.
• Chronic dilution / reverse-split history: Aurora has serially issued equity and reverse-split. Any capital raise into a sentiment pop caps upside and re-punishes holders.
• Earnings binary in ~3 trading days (June 11, pre-open) on a thesis that is not earnings-driven uncompensated event risk for a fresh long today.

Setup & Price Structure

• Last ~$3.46–3.59 (May 31–June 4 2026); 52-week range $3.07–$6.67 roughly 48% off the high and only ~13% off the absolute low.
• Sitting below the 20-, 50- and 200-DMAs with no higher-low base and no breakout retest. The cannabis-reclass theme cooled from its April ACCELERATING burst, and while the U.S. complex is re-accelerating into June 29, ACB is diverging weak against it a relative-strength red flag, not a base.
• The only path to a tradable entry is an event-driven gap (an earnings beat or a hearing headline), i.e. binary risk, not structural momentum.
• Beginner-trap matrix: not peak-retail-stretched (it is at lows), not extended above its MAs but it is squarely earnings-in-under-a-week and in averaging-down territory near the 52-week low. No structural reason to add on weakness here.

Catalyst Calendar (next 30 days)

• 2026-06-11 (Thu, pre-open ~8:00am ET) Q4 / Full-Year FY2026 results; call led by CEO Miguel Martin and CFO Simona King. Watch the FY26 medical net-revenue guide ($269–281M), adjusted EBITDA guide ($52–57M), and any FY27 framing. Binary print.
• 2026-06-29 (Mon, 9:00am ET) DEA broad-rescheduling hearing begins, Arlington VA; considers whether marijuana more broadly (including recreational) should move to Schedule III. Runs to ~July 15 (recess July 3, reconvene July 6). Primary sector-sentiment driver for the complex; ACB participates on beta only.
• Ongoing White House / Congress hemp-CBD legislative push (June 5 2026, Marijuana Moment). Two-sided headline risk that can swing sector sentiment intra-week.

What Would Change Our Mind

• Bullish flip to a momentum re-entry: a clean earnings beat with a raised FY27 guide that produces an event-driven breakout reclaiming the 50-DMA on expanding volume, OR a June 29 hearing headline telegraphing a broad recreational Schedule-III path while ACB carves a higher low. Either would convert this from a probe into a setup worth sizing.
• Re-rate toward MEDIUM only if ACB begins LEADING the complex rather than lagging relative strength versus MSOS/TLRY instead of the June 4 divergence.
• Bearish confirmation: a weekly close below $3.07; a dilutive equity raise announced into a pop; a medical-revenue guide cut on the June 11 print; or the June 29 hearing staying medical-only with no recreational read-through.

Correlation Notes

• ACB trades as a high-beta sentiment proxy to the cannabis complex MSOS, TLRY, CGC, CRON with almost no idiosyncratic U.S.-policy economics of its own. On hearing-headline days it decouples from fundamentals and moves with the ETF.
• The actual reschedule beneficiaries are U.S. multi-state operators (GTBIF, CURLF, TCNNF) and the MSOS ETF; those are the clean expressions of the April 24 / June 29 catalyst. A reader wanting the policy trade is better positioned in U.S. exposure.
• FX/jurisdiction: a CAD-reporting, U.S.-listed LP whose real franchise is international medical (Germany, Poland, Australia, UK), which is less tied to U.S. scheduling than to EU import quotas and Australian script growth.
• Low-dollar, heavy-retail float drives violent, fundamentals-detached spikes on sector news useful for a binary probe, dangerous for a structural position.